All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
4SC AG's histone deacetylase (HDAC) inhibitor resminostat attained the primary endpoint of a Phase II trial in patients with relapsed or refractory Hodgkin's lymphoma (HL).